NASDAQ: TPTX - Turning Point Therapeutics, Inc.

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Turning Point Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Turning Point Therapeutics, Inc.

Turning Point Therapeutics, Inc., биофармацевтическая компания, работающая на клинической стадии, занимается проектированием и разработкой новых низкомолекулярных таргетных онкологических препаратов. Он разрабатывает набор ингибиторов тирозинкиназы (TKI), который нацелен на генетические факторы рака у пациентов, ранее не получавших TKI, и пациентов, получавших лечение TKI.

more details
Ведущий кандидат в лекарственный препарат репотректиниб оценивается в продолжающемся исследовании III фазы под названием TRIDENT-1 для лечения пациентов с распространенным немелкоклеточным раком легкого (НМРЛ) ROS1 + и пациентов с распространенными солидными опухолями ROS1 +, NTRK + или ALK +. Его портфель также включает в себя многоцелевые лекарственные препараты-кандидаты TPX-0046, ингибитор RETSRC; TPX-0022, ингибитор METCSF1RSRC; и TPX-0131, доклинический ингибитор ALK. Компания была основана в 2013 году, ее штаб-квартира находится в Сан-Диего, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2006-10-04
ISIN US90041T1088
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.tptherapeutics.com
Цена ао 75.18
Change price per day: 0% (76.01)
Change price per week: 0% (76.01)
Change price per month: 0% (76.01)
Change price per 3 month: 0% (76.01)
Change price per half year: 0% (76.01)
Change price per year: 0% (76.01)
Change price per 3 year: +118.92% (34.72)
Change price per 5 year: +28.48% (59.16)
Change price per 10 year: 0% (76.01)
Change price per year to date: 0% (76.01)
All parameters

Underestimation

Title Value Grade
P/S 609.13 1
P/BV 4.16 4
P/E 0 0
EV/EBITDA 0.8457 10
Total: 4.13

Efficiency

Title Value Grade
ROA, % -37.07 0
ROE, % -39.18 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0145 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % -89.85 0
Yield Ebitda, % 1222.75 10
Yield EPS, % 315.06 10
Total: 8
More

Institutions Volume Share, %
Fidelity Management & Research Company LLC 3492634 7.25
Cormorant Asset Management, LLC 3037042 6.15
Orbimed Advisors, LLC 2361327 4.78
Fidelity SelectCo, LLC 2012858 4.07
Fidelity Management & Research Company LLC 1974333 4
American Century Investment Management, Inc 934996 1.89
Northern Trust Investments Inc 917027 1.86
Wells Fargo Funds Management LLC 792139 1.6
PGIM Investments LLC 644625 1.3
Fidelity Institutional Asset Management 517107 1.05
Allspring Funds Management LLC 508120 1.03
Candriam Belgium 503875 1.03
Consonance Capital Management LP 450396 0.92
Harbor Capital Advisors Inc 444261 0.9
Hartford Funds Management Company, LLC 405235 0.82
Logos Global Management LP 400000 0.81
First Light Asset Management, LLC 395825 0.8
MPM Oncology Impact Management LP 269186 0.54
Sectoral Asset Management Inc 257379 0.52
BNP Paribas Asset Management Luxembourg 244617 0.5
Nationwide Fund Advisors 137077 0.28
International Biotechnology Trust PLC 121541 0.25
SV Life Sciences Managers LLP 121541 0.25
Federated MDTA LLC 112514 0.23
Parkman Healthcare Partners LLC 110335 0.23
New York Life Investment Management LLC 109243 0.22
Osterweis Capital Management LLC 104585 0.21
The Variable Annuity Life Insurance Company 96043 0.19
MML Investment Advisers, LLC 89844 0.18
Prudential Retirement Services 86566 0.18
Arctic Asset Management AS 77723 0.16
Burrage Capital Management LLC 72164 0.15
Osterweis Capital Management 67400 0.14
Fidelity Investments Canada ULC 49821 0.1
Driehaus Capital Management (USVI) LLC 34985 0.07
AMG Funds LLC 27891 0.06
Nicholas Investment Partners 12856 0.03
Munder Lee Investments Ltd 8117 0.02
First Trust Portfolios L.P. 7079 0.01
Peroni Portfolio Advisors, Inc 400 0

ETF Share, % Profitability for 1 year, % Dividends, %
ProShares UltraShort Nasdaq Biotechnology 0.26 -40.36 1.76



Head Job title Payment Year of birth
Mr. Ed Gemo Sr. VP & Chief Information Officer N/A
Ms. Heather Adams Sr. VP of HR N/A
Dr. Athena Maria Countouriotis M.D. Pres, CEO & Director 1.19M 1972 (53 years)
Mr. Paolo Tombesi Exec. VP & CFO 741.19k 1964 (61 year)
Dr. Adam D. Levy M.B.A., Ph.D. Sr. VP of Investor Relations & Corp. Communications N/A
Mr. Raymond J. Furey J.D. Sr. VP & Chief Compliance Officer N/A 1968 (57 years)
Dr. Mohammad Hirmand Exec. VP & Chief Medical Officer 783.77k 1970 (55 years)
Dr. Gavin Hirst Ph.D. Sr. VP of Chemistry & Interim Chief Scientific Officer N/A
Mr. Brian Sun J.D., M.S. Sr. VP, Gen. Counsel & Corp. Sec. N/A 1984 (41 year)
Dr. Jeffrey P. Whitten Sr. VP of Pre-Clinical Devel.

Address: United States, San Diego, CA , 10628 Science Center Drive - open in Google maps, open in Yandex maps
Website: http://www.tptherapeutics.com